Importantly, a high rate of severe toxicities was observed for CAR-T therapies targeting TAAs including carbonic anhydrase IX (CA IX) in renal cell carcinoma (RCC) [154] and ERBB2 in metastatic CRC [155]. The gene discussed is CA9; the disease is hereditary clear cell renal cell carcinoma.